Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Scheinberg

Showing results (21-30 of 121) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|January 1, 1993
Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemiaP C Caron, D A Scheinberg
Cancer Investigation|January 1, 1997
The biological therapy of acute and chronic leukemiaP C Caron, D A Scheinberg
Oncology (Williston Park, N.Y.)|May 1, 1987
Current status of antitumor therapy with monoclonal antibodiesD A Scheinberg, A N Houghton
Cell Death and Differentiation|May 29, 2002
Ac-225 and her daughters: the many faces of ShivaM R McDevitt, D A Scheinberg
Biochemical and Biophysical Research Communications|March 17, 1995
Substance P and bradykinin are natural inhibitors of CD13/aminopeptidase NY Xu, D Wellner, D A Scheinberg
Experimental Hematology|June 1, 1997
Cryptic and regulatory epitopes in CD13/aminopeptidase NY Xu, D Wellner, D A Scheinberg
Bone Marrow Transplantation|October 26, 2005
Radioimmunoconjugates in acute leukemia treatment: the future is radiantJ Kotzerke, D Bunjes, D A Scheinberg
Blood Reviews|September 30, 2000
CML vaccines as a paradigm of the specific immunotherapy of cancerJ Pinilla-Ibarz, K Cathcart, D A Scheinberg
Science (New York, N.Y.)|March 19, 1982
Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodiesD A Scheinberg, M Strand, O A Gansow
Leukemia|July 1, 1993
Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLLM S Czuczman, K Class, D A Scheinberg
Pageof 13

Showing results (21-30 of 121) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|January 1, 1993
Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemiaP C Caron, D A Scheinberg
Cancer Investigation|January 1, 1997
The biological therapy of acute and chronic leukemiaP C Caron, D A Scheinberg
Oncology (Williston Park, N.Y.)|May 1, 1987
Current status of antitumor therapy with monoclonal antibodiesD A Scheinberg, A N Houghton
Cell Death and Differentiation|May 29, 2002
Ac-225 and her daughters: the many faces of ShivaM R McDevitt, D A Scheinberg
Biochemical and Biophysical Research Communications|March 17, 1995
Substance P and bradykinin are natural inhibitors of CD13/aminopeptidase NY Xu, D Wellner, D A Scheinberg
Experimental Hematology|June 1, 1997
Cryptic and regulatory epitopes in CD13/aminopeptidase NY Xu, D Wellner, D A Scheinberg
Bone Marrow Transplantation|October 26, 2005
Radioimmunoconjugates in acute leukemia treatment: the future is radiantJ Kotzerke, D Bunjes, D A Scheinberg
Blood Reviews|September 30, 2000
CML vaccines as a paradigm of the specific immunotherapy of cancerJ Pinilla-Ibarz, K Cathcart, D A Scheinberg
Science (New York, N.Y.)|March 19, 1982
Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodiesD A Scheinberg, M Strand, O A Gansow
Leukemia|July 1, 1993
Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLLM S Czuczman, K Class, D A Scheinberg
Pageof 13